To investigate the impact of the pharmacological inhibition of MDM2 in a therapeutically relevant setting, we selected RG7112, a pharmacological inhibitor of the MDM2–p53 interaction with demonstrated efficacy in preclinical models of glioblastoma as well as the ability to penetrate the blood–brain barrier, for which clinical information regarding safety is available [20,21,22]. This evidence concerns the gene TP53 and glioblastoma.